اخبار و اعلانات

 آمار

تعداد نشریات285
تعداد نشریات سازمان83
تعداد شماره‌ها3,094
تعداد مقالات34,533
تعداد مشاهده مقاله49,386,437
تعداد دریافت فایل اصل مقاله79,836,660
Falih Soliman, N, Jasim Mohamad, B. (1401). The Impact of CD37 Ectoenzyme Expression in Benign and Malignant Colorectal Tumors. سامانه مدیریت نشریات علمی, 77(6), 2049-2057. doi: 10.22092/ari.2022.358611.2261
N Falih Soliman; B Jasim Mohamad. "The Impact of CD37 Ectoenzyme Expression in Benign and Malignant Colorectal Tumors". سامانه مدیریت نشریات علمی, 77, 6, 1401, 2049-2057. doi: 10.22092/ari.2022.358611.2261
Falih Soliman, N, Jasim Mohamad, B. (1401). 'The Impact of CD37 Ectoenzyme Expression in Benign and Malignant Colorectal Tumors', سامانه مدیریت نشریات علمی, 77(6), pp. 2049-2057. doi: 10.22092/ari.2022.358611.2261
Falih Soliman, N, Jasim Mohamad, B. The Impact of CD37 Ectoenzyme Expression in Benign and Malignant Colorectal Tumors. سامانه مدیریت نشریات علمی, 1401; 77(6): 2049-2057. doi: 10.22092/ari.2022.358611.2261

The Impact of CD37 Ectoenzyme Expression in Benign and Malignant Colorectal Tumors

Archives of Razi Institute
مقاله 5، دوره 77، شماره 6، بهمن و اسفند 2022، صفحه 2049-2057    اصل مقاله (552.18 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2022.358611.2261
نویسندگان
N Falih Soliman* ؛ B Jasim Mohamad
Department of Biology, Collage of Science, University of Baghdad, Baghdad, Iraq
چکیده
The depth of invasion of colorectal cancer through the bowel wall provided the basis for pathological staging. The establishment of prognostic markers for CRC is important in the search for potential targets for therapeutic intervention. The cell surface nucleotidase (CD73) is an enzyme involved in tumor progression and metastasis. Its main function is to convert adenosine monophosphate (AMP) to adenosine. Preclinical studies suggest that CD73 can be targeted for cancer treatment. This study was designed to investigate the prognostic value of CD73 in malignant and benign colorectal tumors among Iraqi patients and its correlation with clinicopathological features using the immunohistochemistry (IHC) technique. In the current study, 60 cases of formalin-fixed paraffin-embedded (FFPE) tissues of colorectal tumors were collected from the Teaching Laboratories of Baghdad Medical City Teaching Hospital, Baghdad – Iraq & private labs in Baghdad. Of them, 52 were malignant, and 8 of benign cases. In addition, 10 cases of the non-pathological significance of colorectal tissues were used as a control group. This study's results revealed significant differences (P=0.001) in the expression of CD73 between malignant tumors and benign and non-significant pathology groups. The highest expression of CD73 was detected in 76.9% of malignant cases, while in the benign group, only 12.5% of cases showed weak positive expression for this marker. Furthermore, significant differences had been reported in CD73 expression with patients' age groups for malignant (P=0.0335), tumor side (P=0.0409), and tumor grade & stage (P=≤0.01). No significant differences had been seen between CD73 expression with tumor diameter and patients' gender.
کلیدواژه‌ها
CD37؛ ectoenzyme؛ colorectal tumors؛ Iraqi patients
سایر فایل های مرتبط با مقاله
مراجع
  1. CABS AJA, Al-Ogaili AAM, FIBOG CHIS. Comparison of colorectal cancer in patients below and above 40 years. 2017.
  2. Salim PM, Abdulla SS, Jalal JA. Immunohistochemical expression of Cyclooxygenase-2 in colorectal carcinoma and its association with clinicopathological parameters. Zanco J Med Sci. 2019;23(3):354-61.
  3. Sulaiman MM, Salih KN. Levels of Interleukin-6 in Colorectal Carcinoma Patients in Relation to Metastasis degree. Med J Tikrit Univ. 2019;25(2).
  4. Fadaka AO, Pretorius A, Klein A. Biomarkers for stratification in colorectal cancer: microRNAs. Cancer Control. 2019;26(1).
  5. Vacante M, Borzì AM, Basile F, Biondi A. Biomarkers in colorectal cancer: Current clinical utility and future perspectives. World J Clin Cases. 2018;6(15):869.
  6. Turano M, Delrio P, Rega D, Cammarota F, Polverino A, Duraturo F, et al. Promising colorectal cancer biomarkers for precision prevention and therapy. Cancers. 2019;11(12):1932.
  7. Wu R, Chen Y, Li F, Li W, Zhou H, Yang Y, et al. Effects of CD73 on human colorectal cancer cell growth in vivo and in vitro. Oncol Rep. 2016;35(3):1750-6.
  8. Messaoudi N, Cousineau I, Arslanian E, Henault D, Stephen D, Vandenbroucke-Menu F, et al. Prognostic value of CD73 expression in resected colorectal cancer liver metastasis. Oncoimmunology. 2020;9(1):1746138.
  9. Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, et al. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother. 2021;70(7):1965-76.
  10. Yang H, Yao F, Davis PF, Tan ST, Hall SR. CD73, tumor plasticity and immune evasion in solid cancers. Cancers. 2021;13(2):177.
  11. De Leve S, Wirsdörfer F, Jendrossek V. Targeting the immunomodulatory CD73/adenosine system to improve the therapeutic gain of radiotherapy. Front Immunol. 2019;10:698.
  12. Zhang B. CD73 promotes tumor growth and metastasis. Oncoimmunology. 2012;1(1):67-70.
  13. Roh M, Wainwright DA, Wu JD, Wan Y, Zhang B. Targeting CD73 to augment cancer immunotherapy. Curr Opin Pharmacol. 2020;53:66-76.
  14. Lafont V, Michaud H-A, Bonnefoy N. CD73: a new biomarker in triple-negative breast cancer. Transl Cancer Res. 2018;7(Suppl 5):S594-S6.
  15. Tsukui H, Horie H, Koinuma K, Ohzawa H, Sakuma Y, Hosoya Y, et al. CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model. BMC Cancer. 2020;20(1):1-12.
  16. Jiang T, Xu X, Qiao M, Li X, Zhao C, Zhou F, et al. Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers. BMC Cancer. 2018;18(1):1-10.
  17. Harvey JB, Phan LH, Villarreal OE, Bowser JL. CD73's potential as an immunotherapy target in gastrointestinal cancers. Front Immunol. 2020;11:508.
  18. Wu XR, He XS, Chen YF, Yuan RX, Zeng Y, Lian L, et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg Oncol. 2012;106(2):130-7.
  19. Wang R, Zhang Y, Lin X, Gao Y, Zhu Y. Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review. Oncotarget. 2017;8(34):57327.
  20. Allard D, Chrobak P, Allard B, Messaoudi N, Stagg J. Targeting the CD73-adenosine axis in immuno-oncology. Immunol Lett. 2019;205:31-9.
  21. Cerbelli B, Botticelli A, Pisano A, Pernazza A, Campagna D, De Luca A, et al. CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. Virchows Archiv. 2020;476(4):569-76.
  22. Ranjbar M-A, Ranjbar Z, Zahed M, Nikookar N. CD73 a novel marker for the diagnosis of benign and malignant salivary gland tumors. J Clin Exp Dent. 2019;11(3):213.
  23. Bertoni APS, Bracco PA, de Campos RP, Lutz BS, Assis-Brasil BM, de Souza Meyer EL, et al. Activity of ecto-5′-nucleotidase (NT5E/CD73) is increased in papillary thyroid carcinoma and its expression is associated with metastatic lymph nodes. Mol Cell Endocrinol. 2019;479:54-60.
  24. Neo SY, Yang Y, Record J, Ma R, Chen X, Chen Z, et al. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. J Clin Invest. 2020;130(3):1185-98.
  25. Zhong J-W, Yang S-X, Chen R-P, Zhou Y-H, Ye M-S, Miao L, et al. Prognostic value of lymphovascular invasion in patients with stage III colorectal cancer: a retrospective study. Med Sci Monit. 2019;25:6043.
  1. Babat I, Polat H, Umar Gursu R, Bashan Y, Kırık A, Bektas H, et al. The effect of mutation status, pathological features and tumor location on prognosis ın patients with colorectal cancer. Rev Assoc Med Bras. 2021;67:185-9.
  2. Zhang B, Song B, Wang X, Chang X-S, Pang T, Zhang X, et al. The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma. Tumor Biol. 2015;36(7):5459-66.
  3. Hu S, Meng F, Yin X, Cao C, Zhang G. NT5E is associated with unfavorable prognosis and regulates cell proliferation and motility in gastric cancer. Biosci Rep. 2019;39(5).
  4. Choi HR, Oh HK, Park SH, Jeong YJ. Expression of CD73 is associated with tumor progression and intratumoral inflammation in breast cancer. Asia Pac J Clin Oncol. 2022;18(1):35-43.
  5. Zheng W, Zhu Y, Chen X, Zhao J. CD73 expression in myeloid-derived suppressor cells is correlated with clinical stages in head and neck squamous cell carcinomas. Ann Transl Med. 2021;9(14).
  6. Dellê H, Ferreira JM, Matheus LHG, Leite KRM, Murta CB, de Almeida Claro JF, et al. Expression balance of ectoenzymes CD39 and CD73 predicts invasiveness in human bladder cancer. Oncotarget. 2021;12(16):1580-6.
  7. Monteiro I, Vigano S, Faouzi M, Treilleux I, Michielin O, Ménétrier-Caux C, et al. CD73 expression and clinical significance in human metastatic melanoma. Oncotarget. 2018;9(42):26659.
آمار
تعداد مشاهده مقاله: 14,681
تعداد دریافت فایل اصل مقاله: 57,579


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب